| | | | Project Site | Date of First | |
|----------------|--------|---|--------------|---------------|--|
| Ethics | IRAS | | R&D | Patient | |
| Committee Ref | Number | Project Title | Submission | Consented | Benchmark Met or Reason for Delay |
| / / | | | | | |
| 15/SC/0287 | 173772 | Provision Of Psychological support to People in Intensive care (POPPI) | 11/07/2015 | 05/09/2015 | Benchmark met |
| /: - / | | CANC-3574 - Nivolumab (BMS-936558) in Stage III (unresectable) or stage | | | |
| 14/LO/1490 | 158617 | IV Melanoma (CA209-172) | 17/07/2015 | 02/09/2015 | Benchmark met |
| | | | | | Delays due to external factors outside the |
| 14/LO/1578 | 156798 | DMID 11-0069 Valgan Toddler | 21/07/2015 | 5 | control of the Sponsor and Trust |
| | | | | | Delays due to external factors outside the |
| 12/YH/0452 | 106985 | INCA | 14/07/2015 | 29/01/2016 | control of the Sponsor and Trust |
| 15/EM/0185 | 167056 | Dietary manipulation in cystic fibrosis related diabetes | 12/08/2015 | | Reasons for delay rest with the Sponsor |
| 13/ ΕΙΝΙ/ 0163 | 10/930 | bietary manipulation in cystic ribrosis related diabetes | 12/06/2013 |) | Delays due to external factors outside the |
| 14/YH/1269 | 160003 | CHIL3644 I.V. Tapentadol in post op pain | 14/08/2015 | | control of the Sponsor and Trust |
| 14/11/1209 | 100993 | Chilbo44 i.v. Tapentadoriii post op pain | 14/06/2013 |) | Reasons for delay rest with both sponsor |
| 15/LO/0517 | 170612 | CANC 4201 VOCEMITE | 11/09/2015 | 14/04/2016 | |
| 15/10/0517 | 170613 | CANC - 4281 - YOSEMITE | 11/08/2015 | 14/04/2016 | Delays due to external factors outside the |
| 15/50/02/12 | 172400 | HAFNA AAAO | 27/09/2015 | | |
| 15/SC/0242 | 1/3490 | HAEM 4448 | 27/08/2015 |) | control of the Sponsor and Trust |
| 14/YH/1090 | 158372 | QUIET-1 | 25/08/2015 | <u>;</u> | Reasons for delay rest with the Sponsor |
| 14/SC/1345 | | PRISM - Progesterone In Spontaneous Miscarriage | 08/09/2015 | | Benchmark met |
| 1 1/30/13 13 | 130320 | EcLiPSE:Emergency treatment with Levetiracetam or Phenytoin in Status | 00,03,2013 | 17,03,2013 | Definition with the control of the c |
| 15/NW/0090 | 162325 | Epilepticus | 11/09/2015 | 05/10/2015 | Benchmark met |
| | | | | | Delays due to external factors outside the |
| 15/NW/0573 | 174966 | CHIL4421 (NP25737) | 10/09/2015 | 5 | control of the Sponsor and Trust |
| , , | | MCRN3102 (SD653) Grunenthal Tapentadol Acute/Postoperative Pain | , , | | · |
| 14/YH/1037 | 149080 | | 23/09/2015 | 21/04/2016 | Reasons for delay rest with the Sponsor |
| 15/WA/0156 | 178291 | , , | 18/09/2015 | | Benchmark met |
| 14/SC/0171 | | Add-Aspirin Trial | 14/09/2015 | | Benchmark met |
| · , | | • | , , , | , , , , , | Delays due to external factors outside the |
| 14/SW/1085 | 161878 | NCRN - 3159 | 07/09/2015 | ; | control of the Sponsor and Trust |
| | | | | | · |
| 14/NI/1113 | 155739 | CONSISTENT CTO | 06/08/2015 | 02/11/2015 | Reasons for delay rest with the Sponsor |
| 14/NI/1114 | 163144 | CELTIC | 06/08/2015 | 12/10/2015 | Benchmark met |

| Fab: as | IDAC | | Project Site | Date of First | |
|-------------------------|--------|--|--------------|---------------|--|
| Ethics | IRAS | Duniosa Tialo | R&D | Patient | Danish was all Mat an Danish for Dalan |
| Committee Ref | Number | Project Title | Submission | Consented | Benchmark Met or Reason for Delay |
| 13/LO/1207 | 86810 | Stereotactic radiotherapy for wet AMD (STAR) | 29/09/2015 | 14/01/2016 | Reasons for delay rest with the Sponsor |
| 15/15/115: | 00020 | (2.7.1.) | 23,03,2023 | 2 1,02,2020 | Delays due to external factors outside the |
| 13/EE/0202 | 89944 | Inter-B-NHL Ritux 2010 | 07/10/2015 | i l | control of the Sponsor and Trust |
| 15/SW/0230 | 181260 | The Bristol Twin (BRIT) Study | 01/10/2015 | 30/10/2015 | Benchmark met |
| 15/LO/1166 | 178877 | Efficacy and Safety of RTH258 versus Aflibercept | 08/10/2015 | 26/11/2015 | Benchmark met |
| 14/LO/2129 | | The VIOLET study | 09/10/2015 | | Benchmark met |
| | | M14-011: Efficacy of the Addition of Veliparib Plus Carboplatin Versus the | | | |
| | | Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus | | | |
| | | Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple | | | |
| 15/LO/0273 | 149700 | Negative Breast Cancer (TNBC) | 14/10/2015 | 09/02/2016 | Reasons for delay rest with the Sponsor |
| 15/LO/0900 | 167412 | 630-0012 Pulmonx LIBERATE Study | 23/10/2015 | 11/11/2015 | Benchmark met |
| 15/SC/0311 | 181166 | VEST III PMS clinical protocol | 13/10/2015 | 11/11/2015 | Benchmark met |
| | | APTITUDE: A phase II trial of Tocilizumab in antiTNF refractory patients | | | |
| 15/LO/0771 | 179095 | with JIA associated uveitis | 29/10/2015 | 20/11/2015 | Benchmark met |
| _ | | | | | |
| 14/WA1205 | 164410 | SPICE III | 26/10/2015 | 12/01/2016 | Reasons for delay rest with the Sponsor |
| | | Improving sexual function after treatment for gynaecological cancer | | | |
| 15/LO/0324 | | (SAFFRON) | 05/11/2015 | | Reasons for delay rest with the Sponsor |
| 14/YH/1202 | | PREVAIL NICU Study | 11/11/2015 | | Benchmark met |
| 14/SC/1312 | 156143 | IMox study | 20/11/2015 | 01/12/2015 | Benchmark met |
| 15/NW/0631 | 185354 | OKAH-193 Varicella vaccine study in the second year of life | 12/11/2015 | 27/01/2016 | Reasons for delay rest with the Sponsor |
| , , , , , , , , , , , , | | MK5172/ MK3682 with MK8742 or MK8408 in HCV GT1, GT2, and GT4 | , , | , , , , , , | , |
| 15/EE/0100 | 163708 | Infected Subjects | 20/11/2015 | 04/12/2015 | Benchmark met |
| 15/LO/0691 | | Checkmate - 171 | 19/11/2015 | | Benchmark met |
| | | | | | Delays due to external factors outside the |
| 15/SC/0397 | 183591 | NJ002: Amino acid feed children?s study | 16/11/2015 | ; | control of the Sponsor and Trust |
| | | · | - | | Delays due to external factors outside the |
| 13/ES/0123 | 119188 | NiCCC Trial (BIBF1120) | 01/12/2015 | 29/02/2016 | control of the Sponsor and Trust |
| 14/WA/1056 | | AML 19 | 03/12/2015 | | Benchmark met |
| 15/WS/0216 | 189003 | BAX855 PUP | 01/12/2015 | 05/01/2016 | Benchmark met |
| 14/SC/1309 | 134909 | The TEMPLATE Study | 11/12/2015 | 15/01/2016 | Benchmark met |

| | | | Project Site | Date of First | |
|---------------|--------|---|--------------|---------------|--|
| Ethics | IRAS | | R&D | Patient | |
| Committee Ref | Number | Project Title | Submission | Consented | Benchmark Met or Reason for Delay |
| 15/WA/0360 | 184197 | The TARGET All Comer Clinical Trial | 10/12/2015 | 17/12/2015 | Benchmark met |
| | | SMTC11004: Paediatric Subjects with Duchenne Muscular Dystrophy | | | |
| 15/LO/0920 | 181642 | (DMD) | 15/12/2015 | 04/02/2016 | Benchmark met |
| | | | | | Delays due to external factors outside the |
| 14/WS/1096 | 149204 | PARADIGM (Cancer) | 26/08/2015 | 27/01/2016 | control of the Sponsor and Trust |
| | | | | | Delays due to external factors outside the |
| 14/LO/1885 | 151063 | EDIBLE v1.0 | 22/12/2015 | | control of the Sponsor and Trust |
| | | Protocol 083: MK5172A + Sofosbuvir +/RBV in Cirrhotic GT3 Subjects (MK- | | | |
| 15/SS/0186 | 190856 | 5172-083) | 19/01/2016 | 28/01/2016 | Benchmark met |
| | | Propel 004 - MSB0010718C in NSCLC - EMR100070004:Phase III study of | | | |
| 15/WS/0121 | 173661 | avelumab vs docetaxel in NSCLC - Javelin Lung 200 | 20/01/2016 | 10/03/2016 | Benchmark met |
| | | | | | Delays due to external factors outside the |
| 14/NE/0103 | 141927 | CaPP3 | 14/01/2016 | 13/04/2016 | control of the Sponsor and Trust |
| 15/SC/0603 | 114842 | CCRN 2393 MAESTRO-OL | 26/01/2016 | 01/03/2016 | Benchmark met |
| | | | | | Delays due to external factors outside the |
| 14/SC/1329 | 157664 | STRIVE | 27/01/2016 | | control of the Sponsor and Trust |
| 15/SW/0008 | 163427 | The Bluebelle study (Phase B) | 22/01/2016 | 02/03/2016 | Benchmark met |
| | | | | | |
| 14/SC/1290 | 141516 | TREATT: Trial to EvaluAte Tranexamic acid therapy in Thrombocytopenia | 27/01/2016 | 19/02/2016 | Benchmark met |
| | | | | | |
| 14/WA/1118 | 159836 | Postoperative adjuvant treatment for HPVpositive tumours (PATHOS) | 01/02/2016 | 09/02/2016 | Benchmark met |
| 15/NW/0416 | 167060 | MUK8 | 02/02/2016 | 1 | Reasons for delay rest with the Trust |
| 15/WM/0415 | 194417 | PRIMAL | 26/01/2016 | 23/02/2016 | Benchmark met |
| 15/SC/0409 | 183061 | OPHT 4170 (AMD) - SEQUOIA | 03/02/2016 | 05/04/2016 | Benchmark met |
| | | | | | |
| 15/EE/0405 | 189187 | DIAB 4501 | 03/02/2016 | , | Reasons for delay rest with the Sponsor |
| | | | | | |
| 15/YH/0407 | 183603 | Single Dose of MK0517 for Prevention of CINV in Paediatric Subjects | 05/02/2016 | | Reasons for delay rest with the Sponsor |
| 15/EM/0300 | 180135 | WO29636 - MPDL3280A in muscle invasive bladder cancer | 26/01/2016 | 23/03/2016 | Benchmark met |
| | | CANC - 4254 - Anti-Pd-L1 Antibody (MPDL3280A) in Pediatric and Young | | | |
| 15/SC/0456 | 174561 | Adult | 09/02/2016 | 24/03/2016 | Benchmark met |
| 14/EM/1284 | 159662 | Neo-AEGIS | 07/01/2016 | 02/03/2016 | Benchmark met |
| 14/YH/0128 | 150031 | SaFaRI (SNS versus the FENIX MSA for adult FI) | 15/02/2016 | 22/02/2016 | Benchmark met |

| Eshi: | IDAC | | Project Site | Date of First | |
|-------------------------|----------------|--|-------------------|----------------------|---|
| Ethics Committee Ref | IRAS Number | Project Title | R&D Submission | Patient Consented | Benchmark Met or Reason for Delay |
| Committee Rei | Itallibei | Troject ritie | | | Deficimiant wice of ricuson for Delay |
| 15/LO/2098 | 182147 | INTEREST: FP-1201-lyo for the treatment of ARDS | 22/01/2016 | 04/04/2016 | Reasons for delay rest with the Sponsor |
| 15/SW/0326 | 189007 | ATLAS: JNJ56021927 (ARN509) | 18/02/2016 | 15/03/2016 | Benchmark met |
| 15/WM/0363 | 184648 | COBALT: Study of Obeticholic Acid in Primary Biliary Cirrhosis (747-302) | 26/01/2016 | | Reasons for delay rest with the Trust |
| | | MLN9708 in Multiple Myeloma Not Treated with Stem Cell | | | Delays due to external factors outside the |
| 15/NE/0167 | 171524 | transplantation - MILLENIUM | 08/03/2016 | | control of the Sponsor and Trust |
| | | | | | Delays due to external factors outside the |
| 15/SW/0179 | 167604 | Injectable Valve Implantation Trial (Invite) | 16/02/2016 | | control of the Sponsor and Trust |
| 14/LO/1206 | 154429 | PLATFORM | 22/02/2016 | 27/04/2016 | Benchmark met |
| 15/EM/0437 | 184390 | COLUMBUS-AMD | 22/03/2016 | 26/05/2016 | Benchmark met |
| | | SCALOP-2: Systemic therapy and Chemoradiation in Advanced LOcalised | | | |
| 15/SC/0103 | 154496 | Pancreatic cancer - 2 | 22/03/2016 | 27/04/2016 | Benchmark met |
| 16 SW 0032 | 190476 | My Health Tag | 23/03/2016 | 14/06/2016 | Reasons for delay rest with the Sponsor |
| 15/NI/00243 | 191267 | Study of CTX 4430 in Cystic Fibrosis Patients | 31/03/2016 | | Reasons for delay rest with the Sponsor |
| 15/LO/1464 | 174042 | DARS | 29/03/2016 | | Reasons for delay rest with the Sponsor |
| 15/NE/0274 | 181026 | EORTC 1320 | 24/03/2016 | | Delays due to external factors outside the control of the Sponsor and Trust |
| 14/EE/1293 | 164389 | C-STICH | 25/02/2016 | 16/06/2016 | Reasons for delay rest with both sponsor and Trust |
| | | WT1TCR -002 Phase I/II study of genemodified WT1 TCR therapy in MDS | | | |
| 14/LO/1644 | 137028 | & AML patient | 28/04/2016 | | 70 days not yet reached |
| 15/LO/0141 | 169126 | OPHT 3845 | 24/03/2016 | | Reasons for delay rest with the Sponsor |
| 15/LO/0413 | 171579 | OPHT 3819 | 12/05/2016 | | 70 days not yet reached |
| 15 /10 /0710 | 177005 | EMBARK:MDV3100-13 Phase3, Enzalutamide, nonmetastatic Prostate | 17/05/2016 | | 70 days not yet reached |
| 15/LO/0710 | 177905 | Cancer | 17/05/2016 | | 70 days not yet reached |

| Ethics | IRAS | | Project Site R&D | Date of First Patient | |
|---------------|--------|--|---------------------|-----------------------|-----------------------------------|
| Committee Ref | Number | Project Title | Submission | Consented | Benchmark Met or Reason for Delay |
| | | | | | |
| | | REGENERATE: A Phase 3, DoubleBlind, Randomized, LongTerm, | | | |
| | | PlaceboControlled, Multicenter Study Evaluating the Safety and Efficacy of | | | |
| 15/YH/0478 | 186697 | Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis | 26/05/2016 | | 70 days not yet reached |
| | | GED-0301-CD-002 PhIII study for subjects with Active Crohn?s Disease | | | |
| 15/ES/0001 | 193859 | (REVOLVE) | 27/04/2016 | | 70 days not yet reached |
| 14/LO/2061 | 162162 | Positioning in Macular Hole Surgery | 07/06/2016 | | 70 days not yet reached |
| 15/EE/0464 | 183877 | CRIT 4440 | 03/06/2016 | | 70 days not yet reached |
| | | LOGS - A randomised phase II/II study to assess the efficacy of Trametinib | | | |
| | | (GSK 1120212) in patients with recurrent of progressive low grade serous | | | |
| 14/ES/1064 | 143994 | ovarian cancer or peritoneal cancer | 15/06/2016 | | 70 days not yet reached |

No of days to First Patient Consented

Reasons for Delays in First Patient Consented



